Company Profile
Daiichi Sankyo Company manufactures and sells pharmaceutical products in Japan and globally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors.
Its portfolio also includes Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3
Symptomatic TGCT, Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia, Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency, and Datroway for the treatment of HR positive and HER2 negative breast cancer NSCLC, as well as Lixiana and Savaysa, which are direct factor Xa inhibitors.
Its portfolio also includes Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents, Nilemdo that lowers cholesterol, Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol, and Efient, an anti-platelet agent. Additionally, it offers Canalia for the treatment of type 2 diabetes mellitus.
Its portfolio also includes Emgality for the treatment of migraine attacks, Pralia for the treatment of osteoporosis and bone erosion associated with rheumatoid arthritis, Ranmark for the treatment of bone complications and GCTB, Tarlige for the treatment of neuropathic pain, Venofer for the treatment of iron deficiency anemia, Vimpat, an anti-seizure medication, and Reyvow for the treatment of acute migraine attacks
Daichirona, a coronavirus RNA vaccine. Its portfolio also includes Flumist, an intranasal live attenuated influenza vaccine, adsorbed cell culture-derived influenza vaccine, measles rubella combined vaccine, and mump vaccine. Founded in 1899 and headquartered in Chuo, Japan, Daiichi Sankyo Company was formerly known as Sankyo Co. Ltd. before rebranding in September 2005.